Fenoterol in asthma.

Abstract

Fenoterol is a beta 2-sympathomimetic bronchodilator. In a double-blind cross-over trial in 17 asthmatic patients with reversible airway obstruction inhalation of both fenoterol (0.4 mg) and terbutaline (0.5 mg) produced a statistically significant greater increase in peak expiratory flow rate than did placebo. The magnitude and duration of response to fenoterol exceeded that to terbutaline in the doses used. The patients' subjective assessment also suggested the relief of their symptoms with the active drugs. Side effects were minimal.

• Authors: G Anderson, E Wilkins, A G Jariwalla
• Journal: British journal of diseases of the chest (Br J Dis Chest) Vol. 73 Issue 1 Pg. 81-4 (Jan 1979) ISSN: 0007-0971 [Print] England
• PMID: 373786 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Ethanolamines
• Fenoterol
• Terbutaline

Topics

• Adult
• Aged
• Asthma (drug therapy, physiopathology)
• Clinical Trials as Topic
• Double-Blind Method
• Ethanolamines (therapeutic use)
• Female
• Fenoterol (therapeutic use)
• Humans
• Male
• Middle Aged
• Peak Expiratory Flow Rate
• Random Allocation
• Terbutaline (therapeutic use)